Direct trial data: the STEP 1 extension reported approximately two-thirds of weight loss regained within one year after stopping semaglutide (Wilding 2022, Diabetes Obes Metab)
Interestingly, semaglutide remained stable for 3 hours at 80 degrees Celsius (176 degrees Fahrenheit) in controlled laboratory conditions, which suggests the molecule is fairly resilient to brief temperature spikes even at extreme levels
This opens the door to a new era of oral small molecule therapies that target the well-validated GLP-1R pathway for metabolic health
With proper monitoring and management, many people successfully take these medications together to address both weight management and conditions requiring spironolactone, such as heart failure, resistant hypertension, or fluid retention
Some of these include AOD-9604, Tirzepatide (SIX DIFFERENT VERSIONS!), and NAD
Concierge Experience Mobile in-home delivery Virtual evaluations